Anacor Pharmaceuticals

Anacor Pharmaceuticals is a biopharmaceutical company dedicated to developing small molecule therapies from its boron chemistry platform. It focuses on the topical application of its compounds to treat fungal, bacterial, and inflammatory diseases. The company's lead product candidate, AN2690, is a novel topical antifungal agent for the treatment of toenail onychomycosis, a fungal infection of the nail and nail bed. It is also developing AN2728, an anti-inflammatory candidate for the treatment of psoriasis; AN0128, a candidate with both antibiotic and anti-inflammatory properties; and AN2718, which is in preclinical development for the topical treatment of vaginal candidiasis and ringworm.